Timing of insertion affects expulsion in patients using the levonorgestrel 52 mg intrauterine system for noncontraceptive indications

Contraception. 2021 Mar;103(3):185-189. doi: 10.1016/j.contraception.2020.11.012. Epub 2020 Dec 5.

Abstract

Objective: To evaluate levonorgestrel 52 mg intrauterine system (IUS) expulsion risk by menstrual cycle day of insertion (days 1-8 vs days 9 and beyond) in women using the IUS for noncontraceptive indications.

Study design: We performed a retrospective cohort study of patients with a levonorgestrel IUS inserted for the management of noncontraceptive, gynecologic conditions at Kaiser Permanente-Hawaii between January 2009 and December 2010. We used multivariable logistic regression models to estimate the likelihood of IUS expulsion adjusting for demographic and clinical factors and a Kaplan-Meier curve for survival analysis.

Results: Of 176 patients identified, insertion occurred in 42 patients in cycle days 1 to 8 and 87 patients after day 8. Patient follow-up within the Kaiser system ranged from 1 to 71 months. Thirty-nine (22%) patients experienced expulsion, 16 (38%) and 15 (17%) for the 2 timing groups, respectively. Expulsion was more likely if the IUS placement occurred during the menstrual cycle days 1 to 8 (adjusted odds ratio 3.57 [95% confidence interval 1.13, 11.31]), which was consistent with the Kaplan-Meier analysis (p = 0.008).

Conclusion: Levonorgestrel IUS expulsion among women using the IUS for noncontraceptive indications occurred more frequently if insertion occurred during the first eight days of the menstrual cycle.

Implications: In women planning to use the levonorgestrel IUS to treat gynecologic conditions such as abnormal uterine bleeding, dysmenorrhea, and endometrial hyperplasia, providers should consider waiting until after cycle day 8 to perform insertion.

Keywords: Abnormal uterine bleeding; Dysmenorrhea; Expulsion; Levonorgestrel 52 mg intrauterine system; Noncontraceptive uses.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Contraceptive Agents, Female*
  • Female
  • Humans
  • Intrauterine Devices, Medicated*
  • Levonorgestrel
  • Menstruation
  • Retrospective Studies

Substances

  • Contraceptive Agents, Female
  • Levonorgestrel